Christoph Neumann-Haefelin
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Shoamanesh A, Mundl H, Smith E, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas J, Dong Q, Turcani P, Christensen H, Ferro J, Veltkamp R, Mikulik R, De Marchis G, Robinson T, Lemmens R, Stepien A, Greisenegger S, Roine R, Csiba L, Khatri P, Coutinho J, Lindgren A, Demchuk A, Colorado P, Kirsch B, Neumann-Haefelin C, Heenan L, Xu L, Connolly S, Hart R, PACIFIC-Stroke Investigators. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2022; 400:997-1007.
Sep 2, 2022Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Sep 2, 2022Lancet 2022; 400:997-1007
Shoamanesh Ashkan, Mundl Hardi, Smith Eric E, Masjuan Jaime, Milanov Ivan, Hirano Teruyuki, Agafina Alina, Campbell Bruce, Caso Valeria, Mas Jean-Louis, Dong Qiang, Turcani Peter, Christensen Hanne, Ferro Jose M, Veltkamp Roland, Mikulik Robert, De Marchis Gian Marco, Robinson Thompson G, Lemmens Robin, Stepien Adam, Greisenegger Stefan, Roine Risto, Csiba Laszlo, Khatri Pooja, Coutinho Jonathan, Lindgren Arne G, Demchuk Andrew M, Colorado Pablo, Kirsch Bodo, Neumann-Haefelin Christoph, Heenan Laura, Xu Lizhen, Connolly Stuart J, Hart Robert G, PACIFIC-Stroke Investigators
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
Dietz J, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C, Buggisch P, Matschenz K, Spengler U, Mullhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer K, Berger A, European HCV Resistance Study Group. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. Clin Gastroenterol Hepatol 2019
Nov 6, 2019Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
Nov 6, 2019Clin Gastroenterol Hepatol 2019
Dietz Julia, Backhus Johanna, Zizer Eugen, Boettler Tobias, Neumann-Haefelin Christoph, Semela David, Stauber Rudolf, Berg Thomas, Berg Christoph, Zeuzem Stefan, Vermehren Johannes, Sarrazin Christoph, Buggisch Peter, Matschenz Katrin, Spengler Ulrich, Mullhaupt Beat, Schulze Zur Wiesch Julian, Piecha Felix, Mauss Stefan, Seegers Barbara, Hinrichsen Holger, Antoni Christoph, Wietzke-Braun Perdita, Peiffer Kai-Henrik, Berger Annemarie, European HCV Resistance Study Group